Show simple item record

dc.contributor.authorFauchier, L
dc.contributor.authorGreenlaw, N
dc.contributor.authorFerrari, R
dc.contributor.authorFord, I
dc.contributor.authorFox, KM
dc.contributor.authorTardif, J-C
dc.contributor.authorTendera, M
dc.contributor.authorSteg, PG
dc.contributor.authorCLARIFY Investigators
dc.date.accessioned2020-12-18T03:11:45Z
dc.date.available2020-12-18T03:11:45Z
dc.date.issued2015
dc.identifierpii: PONE-D-14-50963
dc.identifier.citationFauchier, L., Greenlaw, N., Ferrari, R., Ford, I., Fox, K. M., Tardif, J. -C., Tendera, M., Steg, P. G. & CLARIFY Investigators (2015). Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry.. PLoS One, 10 (4), pp.e0125164-. https://doi.org/10.1371/journal.pone.0125164.
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/11343/255670
dc.description.abstractBACKGROUND: Few data are available regarding the use of antithrombotic strategies in coronary artery disease patients with atrial fibrillation (AF) in everyday practice. We sought to describe the prevalence of AF and its antithrombotic management in a contemporary population of patients with stable coronary artery disease. METHODS AND FINDINGS: CLARIFY is an international, prospective, longitudinal registry of outpatients with stable coronary artery disease, defined as prior (≥12 months) myocardial infarction, revascularization procedure, coronary stenosis >50%, or chest pain associated with evidence of myocardial ischemia. Overall, 33,428 patients were screened, of whom 32,954 had data available for analysis at baseline; of these 2,229 (6.7%) had a history of AF. Median (interquartile range) CHA2DS2-VASc score was 4 (3, 5). Oral anticoagulation alone was used in 25.7%, antiplatelet therapy alone in 52.8% (single 41.8%, dual 11.0%), and both in 21.5%. OAC use was independently associated with permanent AF (p<0.001), CHA2DS2-VASc score (p=0.006), pacemaker (p<0.001), stroke (p=0.04), absence of angina (p=0.004), decreased left ventricular ejection fraction (p<0.001), increased waist circumference (p=0.005), and longer history of coronary artery disease (p=0.008). History of percutaneous coronary intervention (p=0.004) and no/partial reimbursement for cardiovascular medication (p=0.01, p<0.001, respectively) were associated with reduced oral anticoagulant use. CONCLUSIONS: In this contemporary cohort of patients with stable coronary artery disease and AF, most of whom are theoretical candidates for anticoagulation, oral anticoagulants were used in only 47.2%. Half of the patients received antiplatelet therapy alone and one-fifth received both antiplatelets and oral anticoagulants. Efforts are needed to improve adherence to guidelines in these patients. TRIAL REGISTRATION: ISRCTN registry of clinical trials: ISRCTN43070564.
dc.languageeng
dc.publisherPublic Library of Science (PLoS)
dc.titleUse of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry.
dc.typeJournal Article
dc.identifier.doi10.1371/journal.pone.0125164
melbourne.affiliation.departmentMedicine and Radiology
melbourne.source.titlePLoS One
melbourne.source.volume10
melbourne.source.issue4
melbourne.source.pagese0125164-
dc.rights.licenseCC BY
melbourne.elementsid1195065
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411156
melbourne.contributor.authorAjani, Andrew
melbourne.contributor.authorBetter, Nathan
dc.identifier.eissn1932-6203
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record